share_log
Reuters ·  Feb 12 21:01
Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
1
Comment Comment · Views 375

Recommended

Write a comment